PriceTargets.com logo

Neumora Therapeutics - NMRA Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $23.40
  • Forecasted Upside: 109.49%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$11.17 As of 12/30/2024 12:57 PM ET
▼ -0.16 (-1.41%)

This chart shows the closing price for NMRA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Neumora Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NMRA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NMRA

Analyst Price Target is $23.40
▲ +109.49% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Neumora Therapeutics in the last 3 months. The average price target is $23.40, with a high forecast of $30.00 and a low forecast of $15.00. The average price target represents a 109.49% upside from the last price of $11.17.

This chart shows the closing price for NMRA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 6 investment analysts is to moderate buy stock in Neumora Therapeutics. This rating has held steady since December 2023, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/8/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/6/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/4/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/3/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/2/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/30/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/29/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/29/2024

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/16/2024HC WainwrightReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
11/22/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$29.00 ➝ $29.00
11/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
11/13/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$23.00 ➝ $23.00
11/5/2024JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$18.00 ➝ $15.00
10/18/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$23.00 ➝ $23.00
10/1/2024HC WainwrightInitiated CoverageBuy$30.00
9/12/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$23.00 ➝ $23.00
9/4/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$29.00 ➝ $29.00
8/7/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$23.00 ➝ $23.00
7/22/2024Needham & Company LLCInitiated CoverageBuy$23.00
7/8/2024MizuhoInitiated CoverageOutperform$20.00
4/12/2024William BlairReiterated RatingOutperform
3/28/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$31.00
3/18/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$20.00 ➝ $22.00
12/12/2023Deutsche Bank AktiengesellschaftInitiated CoverageHold$13.00
11/8/2023JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$21.00 ➝ $20.00
10/10/2023JPMorgan Chase & Co.Initiated CoverageOverweight$21.00
10/10/2023Bank of AmericaInitiated CoverageBuy$18.00
10/10/2023William BlairInitiated CoverageOutperform ➝ Outperform$26.00
10/10/2023GuggenheimInitiated CoverageBuy$22.00
10/10/2023Royal Bank of CanadaInitiated CoverageOutperform$24.00
10/10/2023Stifel NicolausInitiated CoverageBuy$26.00
(Data available from 12/30/2019 forward)

News Sentiment Rating

0.83 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/3/2024
  • 3 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
7/3/2024
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/2/2024
  • 7 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/1/2024
  • 8 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2024
  • 11 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2024
  • 5 very positive mentions
  • 14 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
11/30/2024
  • 11 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
12/30/2024

Current Sentiment

  • 11 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Neumora Therapeutics logo
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
Read More

Today's Range

Now: $11.17
Low: $10.90
High: $11.51

50 Day Range

MA: $11.07
Low: $9.66
High: $14.05

52 Week Range

Now: $11.17
Low: $8.33
High: $21.00

Volume

222,173 shs

Average Volume

748,606 shs

Market Capitalization

$1.80 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.34

Frequently Asked Questions

What sell-side analysts currently cover shares of Neumora Therapeutics?

The following Wall Street research analysts have issued research reports on Neumora Therapeutics in the last twelve months: HC Wainwright, JPMorgan Chase & Co., Mizuho, Needham & Company LLC, Royal Bank of Canada, and William Blair.
View the latest analyst ratings for NMRA.

What is the current price target for Neumora Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Neumora Therapeutics in the last year. Their average twelve-month price target is $23.40, suggesting a possible upside of 109.5%. HC Wainwright has the highest price target set, predicting NMRA will reach $30.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $15.00 for Neumora Therapeutics in the next year.
View the latest price targets for NMRA.

What is the current consensus analyst rating for Neumora Therapeutics?

Neumora Therapeutics currently has 1 hold rating and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for NMRA.

What other companies compete with Neumora Therapeutics?

Other companies that are similar to Neumora Therapeutics include Halozyme Therapeutics, Krystal Biotech, Scholar Rock, ADMA Biologics and Arcellx. Learn More about companies similar to Neumora Therapeutics.

How do I contact Neumora Therapeutics' investor relations team?

The company's listed phone number is 857-760-0900 and its investor relations email address is [email protected]. The official website for Neumora Therapeutics is neumoratx.com. Learn More about contacing Neumora Therapeutics investor relations.